Search
User Avatar Login
The Defender
  • Explore The Defender
  • Categories
    • CHD.TV
  • Explore CHD.TV
  • Archive
    • Resources
  • Explore Our Resources
  • CHD Bookstore
  • CHD Films
  • eBooks
    • Community
  • Explore Advocacy
  • Community
  • Advocacy Help
    • Science
  • Explore the Science Section
  • Science Library
  • Vaccines
  • Electromagnetic Radiation
    • Legal Justice
  • Explore Litigation
  • Learn The Law
    • About Us
  • About Children’s Health Defense
  • More from CHD
    • Vax-Unvax: Let The Science Speak Home › Citations

    Chapter 10

    This is a listing of all citations in this chapter.

    1

    Kenichiro Sato et al., “Facial Nerve Palsy Following the Administration of COVID-19 mRNA Vaccines: Analysis of a Self-Reporting Database,” International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases 111, (2021): 310–312, doi:10.1016/j.ijid.2021.08.071.

    2

    Kenichiro Sato et al., “Facial Nerve Palsy Following the Administration of COVID-19 mRNA Vaccines: Analysis of a Self-Reporting Database,” International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases 111, (2021): 310–312, doi:10.1016/j.ijid.2021.08.071.

    3

    National Institute of Neurological Disorders and Stroke, “Bell’s Palsy” Accessed on April 16, 2023.

    4

    Erik Y. F. Wan et al., “Bell’s Palsy Following Vaccination with mRNA (BNT162b2) and Inactivated (CoronaVac) SARS-CoV-2 Vaccines: A Case Series and Nested Case-Control Study,” The Lancet Infectious Diseases 22, no. 1 (2022): 64-72, doi:10.1016/S1473-3099(21)00451-5.

    5

    Erik Y. F. Wan et al., “Bell’s Palsy Following Vaccination with mRNA (BNT162b2) and Inactivated (CoronaVac) SARS-CoV-2 Vaccines: A Case Series and Nested Case-Control Study,” The Lancet Infectious Diseases 22, no. 1 (2022): 64-72, doi:10.1016/S1473-3099(21)00451-5.

    6

    Rana Shibili et al., “Association Between Vaccination with the BNT162b2 mRNA COVID-19 Vaccine and Bell’s Palsy: A Population-Based Study,” The Lancet Regional Health. Europe 11 (2021); 100236, doi:10.1016/j.lanepe.2021.100236.

    7

    Rana Shibili et al., “Association Between Vaccination with the BNT162b2 mRNA COVID-19 Vaccine and Bell’s Palsy: A Population-Based Study,” The Lancet Regional Health. Europe 11 (2021); 100236, doi:10.1016/j.lanepe.2021.100236.

    8

    Rana Shibili et al., “Association Between Vaccination with the BNT162b2 mRNA COVID-19 Vaccine and Bell’s Palsy: A Population-Based Study,” The Lancet Regional Health. Europe 11 (2021); 100236, doi:10.1016/j.lanepe.2021.100236.

    9

    Rana Shibili et al., “Association Between Vaccination with the BNT162b2 mRNA COVID-19 Vaccine and Bell’s Palsy: A Population-Based Study,” The Lancet Regional Health. Europe 11 (2021); 100236, doi:10.1016/j.lanepe.2021.100236.

    10

    Eric Yuk Fai Wan et al., “Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 76, no. 3 (2023); e291–e298, doi:10.1093/cid/ciac460.

    11

    Eric Yuk Fai Wan et al., “Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 76, no. 3 (2023); e291–e298, doi:10.1093/cid/ciac460.

    12

    Eric Yuk Fai Wan et al., “Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study,” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 76, no. 3 (2023); e291–e298, doi:10.1093/cid/ciac460.

    13

    Min S. Kim et al., “Comparative Safety of mRNA COVID-19 Vaccines to Influenza Vaccines: A Pharmacovigilance Analysis Using WHO International Database,” Journal of Medical Virology 94, no. 3 (2022), doi:10.1002/jmv.27424.

    14

    Min S. Kim et al., “Comparative Safety of mRNA COVID-19 Vaccines to Influenza Vaccines: A Pharmacovigilance Analysis Using WHO International Database,” Journal of Medical Virology 94, no. 3 (2022), doi:10.1002/jmv.27424.

    15

    Francisco T. T. Lai et al., “Adverse Events of Special Interest Following the Use of BNT162b2 in Adolescents: A Population-Based Retrospective Cohort Study,” Emerging Microbes and Infections 11, no.1 (2022): 885–893, doi:10.1080/22221751.2022.2050952.

    16

    Francisco T. T. Lai et al., “Adverse Events of Special Interest Following the Use of BNT162b2 in Adolescents: A Population-Based Retrospective Cohort Study,” Emerging Microbes and Infections 11, no.1 (2022): 885–893, doi:10.1080/22221751.2022.2050952.

    17

    Francisco T. T. Lai et al., “Adverse Events of Special Interest Following the Use of BNT162b2 in Adolescents: A Population-Based Retrospective Cohort Study,” Emerging Microbes and Infections 11, no.1 (2022): 885–893, doi:10.1080/22221751.2022.2050952.

    18

    Francisco T. T. Lai et al., “Adverse Events of Special Interest Following the Use of BNT162b2 in Adolescents: A Population-Based Retrospective Cohort Study,” Emerging Microbes and Infections 11, no.1 (2022): 885–893, doi:10.1080/22221751.2022.2050952.

    19

    Cleveland Clinic, “Myocarditis” Accessed on April 16, 2023.

    20

    Cleveland Clinic, “Myocarditis” Accessed on April 16, 2023.

    21

    Øystein Karlstad et al., “SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents,” Journal of American Medical Association Cardiology 7, no. 6 (2022): 600-612, doi:10.1001/jamacardio.2022.0583.

    22

    Øystein Karlstad et al., “SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents,” Journal of American Medical Association Cardiology 7, no. 6 (2022): 600-612, doi:10.1001/jamacardio.2022.0583.

    23

    Martina Patone et al., “Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,” Circulation 146, no. 10: 743-754, doi:10.1161/CIRCULATIONAHA.122.059970.

    24

    Martina Patone et al., “Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex,” Circulation 146, no. 10: 743-754, doi:10.1161/CIRCULATIONAHA.122.059970.

    25

    Anthony Simone et al., “Acute Myocarditis Following a Third Dose of COVID-19 mRNA Vaccination in Adults,” International Journal of Cardiology, 365 (2022): 41–43, doi:10.1016/j.ijcard.2022.07.031.

    26

    Anthony Simone et al., “Acute Myocarditis Following a Third Dose of COVID-19 mRNA Vaccination in Adults,” International Journal of Cardiology, 365 (2022): 41–43, doi:10.1016/j.ijcard.2022.07.031.

    27

    Anthony Simone et al., “Acute Myocarditis Following a Third Dose of COVID-19 mRNA Vaccination in Adults,” International Journal of Cardiology, 365 (2022): 41–43, doi:10.1016/j.ijcard.2022.07.031.

    28

    Francisco Tsz Tsun Lai et al., “Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case-Control Study,” Annals of Internal Medicine 175, no. 3 (2022); 362–370, doi:10.7326/M21-3700.

    29

    Francisco Tsz Tsun Lai et al., “Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case-Control Study,” Annals of Internal Medicine 175, no. 3 (2022); 362–370, doi:10.7326/M21-3700.

    30

    Francisco Tsz Tsun Lai et al., “Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case-Control Study,” Annals of Internal Medicine 175, no. 3 (2022); 362–370, doi:10.7326/M21-3700.